Glucose-Raising Polymorphisms in the Human Clock Gene Cryptochrome 2 (CRY2) Affect Hepatic Lipid Content

Fausto Machicao\textsuperscript{1,2\*}, Andreas Peter\textsuperscript{1,2,3\*}, Jürgen Machann\textsuperscript{1,2,4}, Ingmar Königsrainer\textsuperscript{5}, Anja Böhm\textsuperscript{1,2,3}, Stefan Zoltan Lutz\textsuperscript{1,2,3}, Martin Heni\textsuperscript{1,2,3}, Andreas Fritsche\textsuperscript{1,2,3,6}, Fritz Schick\textsuperscript{1,2,4}, Alfred Königsrainer\textsuperscript{5}, Norbert Stefan\textsuperscript{1,2,3}, Hans-Ulrich Häring\textsuperscript{1,2,3}, Harald Staiger\textsuperscript{1,2,3\*}

\textsuperscript{1} Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich at the University of Tübingen, Tübingen, Germany, \textsuperscript{2} German Center for Diabetes Research (DZD), Tübingen, Germany, \textsuperscript{3} Department of Internal Medicine, Division of Endocrinology, Diabetology, Angiology, Nephrology and Clinical Chemistry, University Hospital Tübingen, Tübingen, Germany, \textsuperscript{4} Department of Diagnostic and Interventional Radiology, Section on Experimental Radiology, University Hospital Tübingen, Tübingen, Germany, \textsuperscript{5} Department of General, Visceral, and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany, \textsuperscript{6} Department of Internal Medicine, Division of Nutritional and Preventive Medicine, University Hospital Tübingen, Tübingen, Germany

\* These authors contributed equally to this work.
\* harald.staiger@med.uni-tuebingen.de

Abstract

Circadian rhythms govern vital functions. Their disruption provokes metabolic imbalance favouring obesity and type-2 diabetes. The aim of the study was to assess the role of clock genes in human prediabetes. To this end, genotype-phenotype associations of 121 common single nucleotide polymorphisms (SNPs) tagging \textit{ARNTL}, \textit{ARNTL2}, \textit{CLOCK}, \textit{CRY1}, \textit{CRY2}, \textit{PER1}, \textit{PER2}, \textit{PER3}, and \textit{TIMELESS} were assessed in a study population of 1,715 non-diabetic individuals metabolically phenotyped by 5-point oral glucose tolerance tests. None of the tested SNPs was associated with body fat content, insulin sensitivity, or insulin secretion. Four \textit{CRY2} SNPs were associated with fasting glycaemia, as reported earlier. Importantly, carriers of these SNPs’ ‘minor alleles revealed elevated fasting glycaemia and, concomitantly, reduced liver fat content. In human liver tissue samples, \textit{CRY2} mRNA expression was directly associated with hepatic triglyceride content. Our data may point to \textit{CRY2} as a novel switch in hepatic fuel metabolism promoting triglyceride storage and, concomitantly, limiting glucose production. The anti-steatotic effects of the glucose-raising \textit{CRY2} alleles may explain why these alleles do not increase type-2 diabetes risk.
Introduction

Circadian rhythms control behavioural aspects, such as sleeping/waking, eating, and socializing. Modern lifestyle, characterized by flexible working hours, long-distance flights, and 24-h service offerings, increasingly disrupts this rhythmicity. Disruption of circadian rhythms does not only affect neurotransmitter release in the brain, but also impairs cellular metabolism in peripheral organs promoting metabolic imbalance of the whole body [1]. Thus, night shift workers experience not only mental and social changes but also increments in abdominal fat mass and plasma glucose concentrations and emergence of atherogenic plasma lipid profiles that promote the development of the metabolic syndrome, type-2 diabetes, and coronary heart disease [2–4].

The endogenous clock is hierarchically organized with a central clock located in the suprachiasmatic nucleus that indirectly senses light and synchronizes the peripheral clocks via neuronal and humoral signals [5,6]. Molecularly, the central and peripheral clocks are similarly composed of oscillating concentrations of transcriptional regulators [7,8]: the core clock is formed by the transcription factor heterodimer CLOCK (circadian locomotor output cycles kaput)—BMAL1 (brain and muscle aryl hydrocarbon receptor nuclear translocator-like [ARNTL] protein 1). Among the hundreds of target genes of CLOCK-BMAL1 are the cryptochrome (CRY) genes CRY1 and CRY2 and the period (PER) genes PER1, PER2, and PER3. Following expression, CRY-PER heterodimers assemble and act as corepressors by binding to and removing the CLOCK-BMAL1 complex from promoters and enhancers, thereby switching off CLOCK-BMAL1-induced gene transcription. In consequence, CRY and PER expression drops again and CLOCK-BMAL1 activity is restored. This oscillating core machinery is complemented by a complex network of additional levels of regulation. For instance, AMP-activated protein kinase senses low energy load in the cell and, in response, phosphorylates and activates casein kinase Iε [9,10]. Active casein kinase Iε phosphorylates CRY-PER, and this leads to CRY-PER degradation, thereby relieving the inhibition of CLOCK-BMAL1 [11]. Moreover, novel clock genes were identified via homology screens, such as ARNTL2 and TIMELESS (timeless circadian clock) [12–15], but their exact biological roles are hitherto not well understood.

Few candidate gene studies reported associations of single nucleotide polymorphisms (SNPs) in CLOCK, ARNTL (encoding BMAL1), and PER2 with risk factors for the metabolic syndrome and type-2 diabetes, such as abdominal obesity, hypertension, fatty liver, and an atherogenic lipid profile [16–22]. Moreover, recent genome-wide association (GWA) studies revealed fasting glucose-raising variants in CRY2 which, surprisingly, were not robustly associated with type-2 diabetes [23,24]. Since the role of clock genes in the development of human type-2 diabetes is still unclear, we assessed the impact of common genetic variation in these genes on prediabetic traits in a human study population at increased risk for type-2 diabetes. We genotyped 121 common SNPs tagging ARNTL, ARNTL2, CLOCK, CRY1, CRY2, PER1, PER2, PER3, and TIMELESS and assessed their impact on glycaemia, body fat content, body fat distribution, insulin sensitivity, and insulin release.

Materials and Methods

Ethics Statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (Ethics Committee of the Eberhard Karls University Tübingen) and with the Helsinki Declaration of 1975, as revised in 2000. The study protocol
was approved by the Ethics Committee, and informed written consent was obtained from all participants for being included in the study.

**Study Participants**

The overall study population consisted of 1,715 German individuals recruited from the ongoing Tübingen Family (TÜF) study for type-2 diabetes which currently comprises more than 2,500 non-related individuals at increased risk for type-2 diabetes, i.e., non-diabetic subjects with family history of type-2 diabetes, BMI ≥ 27 kg/m², impaired fasting glycaemia, and/or previous gestational diabetes [25]. All TÜF participants underwent assessment of medical history, smoking status, and alcohol consumption habits, physical examination, routine blood tests, and oral glucose tolerance tests (OGTTs). The overall study population consisted of individuals with complete OGTT and genotype data sets and documented absence of medication known to influence glucose tolerance, insulin sensitivity, or insulin secretion. From 1,682 and 1,632 subjects of the overall study population, respectively, bioelectric impedance measurements and C-peptide data were available. Subgroups of 518, 375, 357, and 314 subjects agreed to undergo hyperinsulinaemic-euglycaemic clamps (HECs), magnetic resonance spectroscopy (MRS) of the liver, whole-body magnetic resonance imaging (MRI), and/or intravenous glucose tolerance tests (IVGTTs), respectively. The clinical characteristics of the overall study population and the subgroups are presented in Table 1.

**Clinical Tests**

A standardised 75-g OGTT was performed following a 10-h overnight fast. For the determination of plasma glucose, insulin, and C-peptide levels, venous blood samples were drawn at baseline and at time-points 30, 60, 90, and 120 min of the OGTT [25]. In those subjects who agreed to undergo both the IVGTT and the HEC, the IVGTT was performed after a 10-h overnight fast and prior to the HEC according to the Botnia protocol [26]. After collection of baseline samples (-10 and -5 min), a glucose dose of 0.3 g/kg body weight was given at time-point 0. Blood samples for the measurement of plasma glucose and insulin were obtained at 2, 4, 6, 8, 10, 20, 30, 40, 50, and 60 min of the IVGTT. The HEC was performed starting at 60 min after the IVGTT glucose bolus. To this end, subjects received a primed infusion of short-acting human insulin (40 mU/m²/min) for 120 min. A variable infusion of 20% glucose was started to clamp the plasma glucose concentration at fasting levels. Blood samples for the measurement of plasma glucose were obtained at 5-min intervals. Plasma insulin levels were measured at baseline (prior to the IVGTT glucose bolus) and at the steady state (the last 30 min) of the clamp. In subjects who agreed to undergo the HEC, but not the IVGTT, the HEC was started immediately after the 10-h overnight fast.

**Measurements of Body Fat Content and Body Fat Distribution**

BMI was calculated as weight divided by squared height (in kg/m²), the percentage of body fat was measured by bioimpedance (BIA-101, RJL systems, Detroit, MI, USA). Whole-body MRI was performed to determine total adipose tissue (TAT) and visceral adipose tissue (VAT) contents [27]. The intrahepatic lipid (IHL) content was quantified by localized stimulated echo acquisition mode ¹H-MRS [28].

**Laboratory Measurements**

Plasma glucose (in mmol/L) was measured with a bedside glucose analyser (glucose oxidase method, Yellow Springs Instruments, Yellow Springs, OH, USA). Serum insulin and C-peptide
The OGTT-derived insulin sensitivity index (ISI OGTT) was calculated as $10,000/[c(\text{Glc}_0) \times c(\text{Ins}_0) \times c(\text{Glc}_{\text{mean}}) \times c(\text{Ins}_{\text{mean}})]^{1/2}$ (with $c$ = concentration, Glc = glucose, and Ins = insulin) [29]. The HEC-derived ISI (ISI HEC) was calculated as glucose infusion rate necessary to maintain euglycaemia during the last 20 min (steady state) of the clamp (in $\mu$mol/kg/min) divided by the steady-state insulin concentration (in pmol/L). Insulin secretion was estimated by three indices: OGTT-derived insulin secretion was calculated as area under the curve (AUC) $\text{Ins}_0-30/AUC_{\text{Glc}_0-30}$ and $\text{AUCC-Pep}_0-120/AUC_{\text{Glc}_0-120}$ (with C-Pep = C-peptide). $AUC_{\text{Ins}_0-30}/AUC_{\text{Glc}_0-30}$ was calculated as $[c(\text{Ins}_0) + c(\text{Ins}_{30})]/[c(\text{Glc}_0) + c(\text{Glc}_{30})]$. $AUC_{\text{C-Pep}_0-120}/AUC_{\text{Glc}_0-120}$ was calculated, according to the trapezoid method, as $\frac{1}{2}[\frac{1}{2}c(\text{C-Pep}_0) + c(\text{C-Pep}_{30}) + c(\text{C-Pep}_60) + c(\text{C-Pep}_{90}) + \frac{1}{2}c(\text{C-Pep}_{120})] + \frac{1}{2}[\frac{1}{2}c(\text{Glc}_0) + c(\text{Glc}_{30}) + c(\text{Glc}_{60}) + c(\text{Glc}_{90}) + \frac{1}{2}c(\text{Glc}_{120})]$. Both indices were previously shown to be well-suited to detect genetically limited $\beta$-cell function [30]. The acute insulin response (AIR) during the IVGTT was calculated as $\frac{1}{2}[\frac{1}{2}c(\text{Ins}_0) + c(\text{Ins}_2) + c(\text{Ins}_4) + c(\text{Ins}_8) + c(\text{Ins}_{10})]$. 

### Calculations

The OGTT-derived insulin sensitivity index (ISI OGTT) was calculated as $10,000/[c(\text{Glc}_0) \times c(\text{Ins}_0) \times c(\text{Glc}_{\text{mean}}) \times c(\text{Ins}_{\text{mean}})]^{1/2}$ (with $c$ = concentration, Glc = glucose, and Ins = insulin) [29]. The HEC-derived ISI (ISI HEC) was calculated as glucose infusion rate necessary to maintain euglycaemia during the last 20 min (steady state) of the clamp (in $\mu$mol/kg/min) divided by the steady-state insulin concentration (in pmol/L). Insulin secretion was estimated by three indices: OGTT-derived insulin secretion was calculated as area under the curve (AUC) $\text{Ins}_0-30/AUC_{\text{Glc}_0-30}$ and $\text{AUCC-Pep}_0-120/AUC_{\text{Glc}_0-120}$ (with C-Pep = C-peptide). $AUC_{\text{Ins}_0-30}/AUC_{\text{Glc}_0-30}$ was calculated as $[c(\text{Ins}_0) + c(\text{Ins}_{30})]/[c(\text{Glc}_0) + c(\text{Glc}_{30})]$. $AUC_{\text{C-Pep}_0-120}/AUC_{\text{Glc}_0-120}$ was calculated, according to the trapezoid method, as $\frac{1}{2}[\frac{1}{2}c(\text{C-Pep}_0) + c(\text{C-Pep}_{30}) + c(\text{C-Pep}_60) + c(\text{C-Pep}_{90}) + \frac{1}{2}c(\text{C-Pep}_{120})] + \frac{1}{2}[\frac{1}{2}c(\text{Glc}_0) + c(\text{Glc}_{30}) + c(\text{Glc}_{60}) + c(\text{Glc}_{90}) + \frac{1}{2}c(\text{Glc}_{120})]$. Both indices were previously shown to be well-suited to detect genetically limited $\beta$-cell function [30]. The acute insulin response (AIR) during the IVGTT was calculated as $\frac{1}{2}[\frac{1}{2}c(\text{Ins}_0) + c(\text{Ins}_2) + c(\text{Ins}_4) + c(\text{Ins}_8) + c(\text{Ins}_{10})]$. 

### Table 1. Clinical data of the overall study population and the subgroups.

| Parameter                        | Overall population (N = 1,715) | Bioimpedance (N = 1,682) | C-Peptide data (N = 1,632) | HEC (N = 518) | MRS (N = 375) | MRI (N = 357) | IVGTT (N = 314) |
|----------------------------------|---------------------------------|--------------------------|---------------------------|---------------|---------------|---------------|----------------|
| N (women/men)                    | 1,122/593                       | 1,105/577                | 1,072/560                 | 274/244       | 238/137       | 222/135       | 180/134        |
| Age (y)                          | 39 ± 12                         | 39 ± 12                  | 39 ± 12                   | 40 ± 12       | 45 ± 12       | 45 ± 12       | 45 ± 11         |
| BMI (kg/m²)                      | 30.0 ± 9.1                      | 29.9 ± 8.9               | 30.2 ± 9.2                | 27.3 ± 5.7    | 30.1 ± 5.1    | 30.0 ± 5.3    | 29.4 ± 5.7      |
| NGT/IFG/IGT/IGT + IGT           | 1,211/194/162/148               | 1,193/189/166/134        | 1,148/187/153/144         | 397/40/38/33  | 236/50/48/41  | 225/43/49/40  | 210/32/43/29/29 |
| Glucose, fasting (mmol/L)        | 5.14 ± 0.55                     | 5.13 ± 0.55              | 5.14 ± 0.56               | 5.02 ± 0.53   | 5.26 ± 0.50   | 5.23 ± 0.50   | 5.18 ± 0.49     |
| 2-h Glucose (mmol/L)             | 6.34 ± 1.65                     | 6.34 ± 1.64              | 6.36 ± 1.64               | 6.17 ± 1.70   | 6.93 ± 1.54   | 6.92 ± 1.58   | 6.77 ± 1.66     |
| ISI, OGTT (x 10$^{19}$ L$^{-2}$ x mol$^{-2}$) | 15.5 ± 10.7                     | 15.7 ± 10.7              | 15.5 ± 10.8               | 18.2 ± 11.2   | 12.3 ± 6.7    | 12.6 ± 6.9    | 14.0 ± 7.9      |
| Body fat content (%)             | -                               | 32.4 ± 12.0              | 32.4 ± 12.0               | 28.2 ± 9.7    | 33.7 ± 9.2    | 33.0 ± 8.9    | 31.8 ± 8.9      |
| AUC$_{\text{Ins}_0-30}/$AUC$_{\text{Glc}_0-30}$ (x 10$^{-9}$) | -                            | -                         | 43.8 ± 32.4               | 37.2 ± 24.8   | 43.1 ± 27.1   | 42.3 ± 27.2   | 40.6 ± 24.9     |
| AUC$_{\text{C-Pep}_0-120}/$AUC$_{\text{Glc}_0-120}$ (x 10$^{-9}$) | -                            | -                         | 321 ± 104                 | 311 ± 97      | 306 ± 87      | 306 ± 90      | 307 ± 92        |
| ISI, HEC (x 10$^{9}$ L x kg$^{-1}$ x min$^{-1}$) | -                            | -                         | -                         | 0.084 ± 0.052 | -              | -             | 0.069 ± 0.041   |
| IHL (% signal)                   | -                               | -                         | -                         | 5.99 ± 6.49   | 5.96 ± 6.46   | -             | -              |
| TAT (% body weight)              | -                               | -                         | -                         | -              | 30.5 ± 9.1    | -             | -              |
| VAT (% body weight)              | -                               | -                         | -                         | -              | 3.33 ± 1.70   | -             | -              |
| AIR (pmol/L)                     | -                               | -                         | -                         | -              | -             | -             | 933 ± 629       |

Data are given as counts or means ±SD. AIR—acute insulin response; AUC—area under the curve; BMI—body mass index; C-Pep—C-peptide; Glc—glucose; HEC—hyperinsulinaemic-euglycaemic clamp; IFG—impaired fasting glycaemia; IGT—impaired glucose tolerance; IHL—intrahepatic lipids; Ins—insulin; ISI—insulin sensitivity index; IVGTT—intravenous glucose tolerance test; MRI—magnetic resonance imaging; MRS—magnetic resonance spectroscopy; NGT—normal glucose tolerance; OGTT—oral glucose tolerance test; TAT—total adipose tissue; VAT—visceral adipose tissue.

doi:10.1371/journal.pone.0145563.t001
Selection of Tagging SNPs and Genotyping

Based on publicly available HapMap-CEU data (Release #28; http://hapmap.ncbi.nlm.nih.gov/index.html.en) and the tagger function of Haploview 4.2 (http://www.broadinstitute.org.haploview/haploview), we identified 121 SNPs tagging all common SNPs (minor allele frequencies ≥ 0.05) in the ARNTL, ARNTL2, CLOCK, CRY1, CRY2, PER1, PER2, PER3, and TIMELESS loci (gene regions and up to 5 kb of 5’- and 3’-flanking regions) with an r² ≥ 0.8. Information about the genomic localisation of the tagging SNPs is given in S1 Table. For genotyping, DNA was isolated from whole blood using a commercial kit (NucleoSpin, Macherey & Nagel, Düren, Germany). The tagging SNPs were genotyped by mass spectrometry (massARRAY, Sequenom, Hamburg) and the manufacturer’s iPLEX software, and SNPs that resisted massARRAY’s multiplex design were genotyped with TaqMan assays (Applied Biosystems, Foster City, CA, USA). Eleven SNPs were excluded from further analyses due to failure to achieve Hardy-Weinberg equilibrium (p < 0.05). The genotyping results including call rates, minor allele frequencies, and p-values for Hardy-Weinberg equilibrium are given in S1 Table. The 110 tagging SNPs that were followed-up in association analyses covered 76% of common SNPs in ARNTL, 79% in ARNTL2, 99% in CLOCK, 97% in CRY1, 100% in CRY2, 86% in PER1, 83% in PER2, 56% in PER3, and 100% in TIMELESS.

Human Liver Tissue Collection

A total of 92 German individuals (34 women/58 men; age 62 ± 12 y, BMI 25 ± 4 kg/m²) undergoing liver surgery was included in the present study. The patients were fasted overnight prior to collection of the liver biopsies. The subjects were tested negative for viral hepatitis and had no liver cirrhosis. Liver samples were taken from normal, non-diseased tissue during surgery, immediately frozen in liquid nitrogen, and stored at -80°C.

Determination of Liver Tissue Triglyceride Content and Estimation of de novo Lipogenesis

Liver tissue was homogenized in phosphate-buffered saline containing 1% Triton X-100 using TissueLyser (Qiagen, Hilden, Germany). Triglyceride contents were quantified in the homogenates with the ADVIA 1800 clinical chemistry analyser (Siemens Healthcare Diagnostics, Eschborn, Germany) and are given in percent corresponding to mg/100 mg tissue [31]. To estimate fatty acid biosynthesis, the palmitate-linoleate ratio was calculated as described earlier [32,33]. This de novo lipogenesis index represents the ratio of the main product of fatty acid biosynthesis, i.e., palmitate, and the essential fatty acid linoleate originating from dietary lipids. The index was first evaluated under strictly controlled nutritional conditions [32,33] and later validated in individuals on a habitual diet [34,35]. Separation of liver homogenate extracts into five lipid fractions using thin layer chromatography, trans-esterification of the fatty acids, and quantification by gas chromatography with a flame ionization detector was performed as previously described in detail [34,35].

Determination of Hepatic CRY2 mRNA Expression by Real-Time Reverse Transcription PCR

Liver tissue was homogenized using TissueLyser (Qiagen), and total RNA was extracted with the RNeasy Tissue Kit from Qiagen according to the manufacturer’s instructions. Total RNA treated with RNase-free DNase I was transcribed into cDNA using Avian myoblastosis virus reverse transcriptase and the first-strand cDNA kit from Roche Diagnostics (Mannheim, Germany). PCR (in technical duplicates) was performed on a LightCycler 480 (Roche Diagnostics)
using Probes Master and fluorescent probes from the Universal Probe Library (Roche Diagnostics). Primers were designed using the Roche Probe Design 2 software (Roche Diagnostics) and purchased from TIB MOLBIOL (Berlin, Germany). Primer sequences and PCR conditions can be provided upon request. CRY2 mRNA data were normalised for the housekeeping gene RPS13 using the ΔΔCt method.

Statistical Analyses

Hardy-Weinberg equilibrium was tested using χ² test (one degree of freedom). Continuous variables with skewed distribution were loge-transformed prior to statistical analysis. Multiple linear regression analysis was performed using the least-squares method. In the regression models, the trait of interest (metabolic endpoint) was chosen as outcome variable, the SNP genotype (in the additive inheritance model) as independent variable, and gender, age, BMI, and ISI OGTT as confounding variables as indicated. For analysis of SNP-gender, SNP-BMI, and SNP-glucose interaction effects on the traits of interest, the respective cross effects were tested by multiple linear regression analysis including the appropriate confounding variables. Conditional SNP analyses were performed by testing all SNPs of interest collectively in one multiple linear regression model. Testing all 110 SNPs in parallel, the study-wide significance threshold was set to p < 0.0005 according to Bonferroni correction for multiple comparisons. In the in vitro follow-up studies, multiple linear regression analysis was performed, and p-values < 0.05 were considered significant. For all analyses, the statistical software JMP 10.0 (SAS Institute, Cary, NC, USA) was used.

Results

The clinical characteristics of the overall study population and the subgroups are given in Table 1. Of the 121 tagging SNPs genotyped, 110 SNPs passed our quality criteria, i.e., they were in Hardy-Weinberg equilibrium (p ≥ 0.05) and/or had a minimum call rate of 90% (S1 Table), and thus entered association analysis.

After appropriate adjustment (body fat was adjusted for gender and age; glucose concentrations and insulin sensitivity for gender, age, and BMI; and insulin secretion for gender, age, BMI, and insulin sensitivity), none of the clock SNPs was significantly associated with body fat content, insulin sensitivity, or insulin secretion (S2–S4 Tables). Nor were significant SNP-gender, SNP-body mass, or SNP-glucose interaction effects observed (S5–S7 Tables).

As shown in S2 and S3 Tables and Fig 1, four of the ten CRY2 SNPs tested were associated with fasting glycaemia (p < 0.004), one of them (rs11605924) reaching study-wide significance (p < 0.0005), and the same SNPs concomitantly revealed nominal associations with liver fat content (p < 0.015). By contrast, the six CRY2 SNPs that were not associated with fasting glycaemia (p ≥ 0.2) also lacked association with liver fat (p ≥ 0.1; S2 and S3 Tables and Fig 1). This obvious congruence argues against mere chance findings and points to closely linked metabolic effects of CRY2 in liver metabolism. Interestingly, carriers of the minor alleles of the four aforementioned SNPs revealed elevated fasting glycaemia and, concomitantly, reduced liver fat content suggesting that these minor alleles may be involved in redirection of intermediary metabolites from hepatic triglyceride synthesis to gluconeogenesis (S2 and S3 Tables).

Upon interrogation of publicly available data from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC), three out of the four CRY2 SNPs, i.e., rs10838524, rs11605924, and rs7933420, revealed very robust effects on fasting glycaemia with congruent effect directions (p < 2.6 x 10⁻⁵, minor alleles increase fasting glycaemia; [23]). The fourth SNP, i.e., rs3824872, only reached nominal association but again with congruent effect direction (p = 0.0205, minor allele increases fasting glycaemia; [23]). Using conditional analysis of
our data, we tested whether the three most robust MAGIC SNPs represent independent signals. Even though incompletely linked ($r^2 < 0.8$), as is characteristic of tagging SNPs, none of the SNPs was, independently of the other two SNPs, associated with fasting glycaemia ($p > 0.077$) or liver fat content ($p > 0.3$). This points to SNP-SNP interactions in *cis* (direct interactions between DNA regions) or *trans* (interactions mediated by DNA-binding factors) within this locus.

To further substantiate our liver fat findings, we assessed the relationship between *CRY2* mRNA expression and hepatic triglyceride content in human liver tissue samples characterized by a wide range of triglyceride content (0.3–17.6%). After adjustment for gender, age, and BMI, *CRY2* mRNA expression was directly associated with the tissue triglyceride content ($r = 0.24$, $p = 0.021$; Fig 2). To estimate whether *CRY2* influences hepatic *de novo* lipogenesis (i.e., fatty acid biosynthesis), we calculated the palmitate-linoleate ratio in the hepatic triglyceride fraction of the liver samples [32,33]. *CRY2* mRNA expression was not significantly associated with the *de novo* lipogenesis index ($p = 0.8$). This suggests an involvement of *CRY2* in re-esterification or lipolysis rather than *de novo* lipogenesis. The sample size of the liver tissue collection was
too small to detect reliable associations between the $CRY2$ SNPs and hepatic $CRY2$ mRNA expression or triglyceride content (data not shown).

**Discussion**

Recent meta-analyses of GWA studies revealed fasting glucose-raising variants in $CRY2$ which, surprisingly, were not robustly associated with an increased risk for type-2 diabetes [23,24]. In this study, we replicated the effects of four $CRY2$ SNPs on fasting glycaemia including their consistent directionality: the minor alleles of all four SNPs were associated with increased fasting glucose concentrations.

More importantly however, we describe herein a novel aspect of the four genetic $CRY2$ variants that may explain their lack of association with type-2 diabetes: the fasting glucose-raising alleles were, concomitantly, associated with ~ 30% reduced liver fat content *in vivo*, and liver fat is a well-recognized risk factor for insulin resistance and type-2 diabetes [36,37]. In agreement with this hypothesis, the SNPs were neither associated with insulin sensitivity nor with
glucose tolerance (2-h glucose concentrations after oral glucose load). Physiologically, our findings suggest that CRY2 may represent an important molecular switch in hepatic lipid and glucose metabolism favoring triglyceride synthesis at the expense of gluconeogenesis, possibly by channeling intermediary metabolites (e.g., glycerol 3-phosphate) from gluconeogenesis to esterification with fatty acids/triglyceride synthesis. This is strengthened by our finding that CRY2 has no effect on de novo lipogenesis/fatty acid biosynthesis.

In accordance with a gluconeogenesis-suppressive effect of CRY2, recently published data points to direct inhibitory interactions of CRY proteins with the glucocorticoid receptor resulting in suppression of glucocorticoid-induced expression of phosphoenolpyruvate carboxykinase 1 [38]. Moreover, Zhang et al. reported that adenoviral CRY1 overexpression in mice inhibits glucagon-stimulated gluconeogenesis through direct interaction with Gsα and glucagon receptor blockade [39]. Due to their structural relatedness, a similar mechanism is also conceivable for CRY2. Unfortunately, the authors did not assess whether inhibition of gluconeogenesis by CRY1 overexpression is accompanied by an accumulation of hepatic lipids. Based on the glucose-lowering effects of CRY1, the authors speculate that CRY activation may represent an option for anti-diabetic therapy [39]. This idea may be supported by the finding that CRY proteins also limit nuclear factor κB-dependent inflammation, a common hallmark of metabolic diseases [40]. As to CRY2, we think however that CRY activation could be hazardous: our SNP data suggest that any supra-physiological enhancement of CRY2 signaling may favor liver fat accumulation and, thus, promote non-alcoholic fatty liver disease and type-2 diabetes. How CRY2 promotes triglyceride synthesis molecularly is currently unknown and deserves further investigations.

The relevance of our negative findings with respect to the impact of ARNTL, ARNTL2, CLOCK, CRY1, PER1, PER2, PER3, and TIMELESS on metabolic traits may be questioned due to the limited sample size of our study population (and in particular of our subgroups) that may be sufficiently powered to reveal only rather strong and robust effects, such as those of CRY2 SNPs on fasting glycaemia. Thus, we cannot exclude that the other clock genes may have modest effects on metabolic traits, and larger studies are needed to address this.

In conclusion, our results support CRY2 as a novel switch in hepatic fuel metabolism promoting triglyceride storage and, concomitantly, limiting glucose production. The anti-steatotic effects of the fasting glucose-raising CRY2 alleles may explain why these alleles do not increase type-2 diabetes risk. Moreover, if translatable into the prospective setting, this finding may limit the common assumption that increased fasting glycaemia is generally predictive for future type-2 diabetes.

Supporting Information
S1 Table. Genomic localization of the 121 clock SNPs and genotyping results.
(DOC)

S2 Table. SNP associations with body fat content/distribution.
(DOC)

S3 Table. SNP associations with glycaemia and insulin sensitivity.
(DOC)

S4 Table. SNP associations with insulin secretion.
(DOC)

S5 Table. SNP-gender interaction effects on BMI, body fat content, glucose concentrations, insulin sensitivity, and insulin secretion.
(DOC)
S6 Table. SNP-BMI interaction effects on glucose concentrations, insulin sensitivity, and insulin secretion.

(DOC)

S7 Table. SNP-glucose interaction effects on insulin secretion.

(DOC)

Acknowledgments

We thank all study participants for their cooperation. We gratefully acknowledge the excellent technical assistance of Carina Hermann, Mareike Walenta, Alke Guirguis, and Roman-Georg Werner.

Author Contributions

Conceived and designed the experiments: AF FS AK NS HUH. Performed the experiments: FM AP JM IK AB SZL MH. Analyzed the data: FM AP HS. Wrote the paper: HS FM AP JM AF FS AK NS HUH.

References

1. Eckel-Mahan K, Sassone-Corsi P. Metabolism and the circadian clock converge. Physiol Rev. 2013; 93: 107–135. doi: 10.1152/physrev.00016.2012 PMID: 23303907

2. Froy O. Metabolism and circadian rhythms—implications for obesity. Endocr Rev. 2010; 31: 1–24. doi: 10.1210/er.2009-0014 PMID: 19854863

3. Szosland D. Shift work and metabolic syndrome, diabetes mellitus and ischaemic heart disease. Int J Occup Environ Health. 2010; 23: 287–291. doi: 10.2478/v10001-010-0032-5 PMID: 20934953

4. Vyas MV, Garg AX, Iansavichus AV, Costella J, Donner A, Laugsand LE et al. Shift work and vascular events: systematic review and meta-analysis. BMJ. 2012; 345: e4800. doi: 10.1136/bmj.e4800 PMID: 22835925

5. Froy O. The circadian clock and metabolism. Clin Sci (Lond). 2011; 120: 65–72.

6. Dibner C, Schibler U. Circadian timing of metabolism in animal models and humans. J Intern Med. 2015; 277: 513–527 doi: 10.1111/joim.12347 PMID: 25599827

7. Huang W, Ramsey KM, Marcheva B, Bass J. Circadian rhythms, sleep, and metabolism. J Clin Invest. 2011; 121: 2133–2141. doi: 10.1172/JCI46043 PMID: 21633182

8. Bass J, Takahashi JS. Circadian Integration of metabolism and energetics. Science. 2010; 330: 1349–1354. doi: 10.1126/science.1195027 PMID: 21127246

9. Um JH, Yang S, Yamazaki S, Kang H, Viollet B, Foretz M et al. Activation of 5'-AMP-activated kinase with diabetes drug metformin induces casein kinase lepsilon (CKIepsilon)-dependent degradation of clock protein mPer2. J Biol Chem. 2007; 282: 20794–20798. PMID: 17525164

10. Bamea M, Haviv L, Gutman R, Chapnik N, Madar Z, Froy O. Metformin affects the circadian clock and metabolic rhythms in a tissue-specific manner. Biochim Biophys Acta. 2012; 1822: 1769–1806. doi: 10.1016/j.bbadis.2012.08.005 PMID: 22968146

11. Eide EJ, Kang H, Crapo S, Gallego M, Virshup DM. Casein kinase I in the mammalian circadian clock. Methods Enzymol. 2005; 393: 408–418. PMID: 15817902

12. Ikeda M, Yu W, Hirai M, Ebisawa T, Honma S, Yoshimura K et al. cDNA cloning of a novel bHLH-PAS transcription factor superfamily gene, BMAL2: its mRNA expression, subcellular distribution, and chromosomal localization. Biochim Biophys Res Commun. 2000; 275: 493–502. PMID: 10964893

13. Maemura K, de la Monte SM, Chin MT, Layne MD, Hsieh CM, Yet SF et al. CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J Biol Chem. 2000; 275: 36847–36851. PMID: 11018023

14. Sangoram AM, Saez L, Antoch MP, Geakkis N, Staknis D, Whiteley A et al. Mammalian circadian auto-regulatory loop: a timeless ortholog and mPer1 interact and negatively regulate CLOCK-BMAL1-induced transcription. Neuron. 1998; 21: 1101–1113. PMID: 9856469

15. Koike N, Hida A, Numano R, Hirose M, Sakaki Y, Tei H. Identification of the mammalian homologues of the Drosophila timeless gene, Timeless1. FEBS Lett. 1998; 441: 427–431. PMID: 9891964
16. Garaulet M, Corbalan-Tutau MD, Madrid JA, Baraza JC, Parnell LD, Lee YC et al. PERIOD2 variants are associated with abdominal obesity, psycho-behavioral factors, and attrition in the dietary treatment of obesity. J Am Diet Assoc. 2010; 110: 917–921. doi: 10.1016/j.jada.2010.03.017 PMID: 20497782

17. Soookoian S, Gemma C, Gianotti TF, Burgueno A, Castano G, Pirola CJ. Genetic variants of Clock transcription factor are associated with individual susceptibility to obesity. Am J Clin Nutr. 2008; 87: 1606–1615. PMID: 18541547

18. Scott EM, Carter AM, Grant PJ. Association between polymorphisms in the Clock gene, obesity and the metabolic syndrome in man. Int J. Obes (Lond). 2008; 32: 658–662.

19. Englund A, Kovanen L, Saarikoski ST, Haukka J, Reunanen A, Aromaa A et al. NPAS2 and PER2 are linked to risk factors of the metabolic syndrome. J Circadian Rhythms. 2009; 7: 5. doi: 10.1186/1740-3391-7-5 PMID: 19470168

20. Woon PY, Kaisaki PJ, Braganca J, Bihoreau MT, Levy JC, Farrall M et al. Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is associated with susceptibility to hypertension and type 2 diabetes. Proc Natl Acad Sci USA. 2007; 104: 14412–14417. PMID: 17728404

21. Soookoian S, Castano G, Gemma C, Gianotti TF, Pirola CJ. Common genetic variations in CLOCK transcription factor are associated with nonalcoholic fatty liver disease. World J Gastroenterol. 2007; 13: 4242–4248. PMID: 17696255

22. Tsuchizaki K, Kotani K, Sano Y, Fujisawa S, Takahashi K, Sakane N. The association of the Clock 3111 T/C SNP with lipids and lipoproteins including small dense low-density lipoprotein: results from the Mima study. BMC Med Genet. 2010; 11: 150. doi: 10.1186/1471-2350-11-150 PMID: 20961464

23. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010; 42: 105–116. doi: 10.1038/ng.520 PMID: 20081858

24. Kelly MA, Reeds SD, Hydrie MZ, Shera AS, Bellary S, O’Hare JP et al. Circadian gene variants and susceptibility to type 2 diabetes: a pilot study. PLoS One. 2012; 7: e32670. doi: 10.1371/journal.pone.0032670 PMID: 22485135

25. Stefan N, Machicao F, Staiger H, Machann J, Schick F, Tschritter O et al. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia. 2005; 48: 2282–2291. PMID: 16205883

26. Tripathy D, Wessman Y, Gullstrom M, Tuomi T, Groop L. Importance of obtaining independent measures of insulin secretion and insulin sensitivity during the same test: results with the Botnia clamp. Diabetes Care. 2003; 26: 1395–1401. PMID: 12716795

27. Machann J, Thamer C, Schoedt B, Haap M, Häring HU, Claussen CD et al. Standardized assessment of whole body adipose tissue topography by MRI. J Magn Reson Imaging. 2005; 21: 455–462. PMID: 15778954

28. Machann J, Thamer C, Schoedt B, Stefan N, Häring HU, Claussen CD et al. Hepatic lipid accumulation in healthy subjects: a comparative study using spectral fat-selective MRI and volume-localized 1H-MR spectroscopy. Magn Reson Med. 2006; 55: 913–917. PMID: 16506186

29. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999; 22: 1462–1470. PMID: 10480510

30. Herzberg-Schafer SA, Staiger H, Heni M, Ketterer C, Guthoff M, Kantartzis K et al. Evaluation of fasting state/oral glucose tolerance test-derived measures of insulin release for the detection of genetically impaired beta-cell function. PLoS One. 2010; 5: e14194. doi: 10.1371/journal.pone.0014194 PMID: 21152029

31. Peter A, Kantartzis K, Machicao F, Machann J, Wagner S, Tempel S et al. Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content. Int J Obes (Lond). 2012; 36: 774–782.

32. Hudgins LC, Hellerstein M, Seidman C, Neese R, Diakun J, Hirsch J. Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet. J Clin Invest. 1996; 97: 2081–2091. PMID: 8621798

33. Chong MF, Hodson L, Bickerton AS, Roberts R, Neville M, Karpe F et al. Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 d of high-carbohydrate feeding. Am J Clin Nutr. 2008; 87: 817–823. PMID: 18400702

34. Peter A, Stefan N, Cegan A, Walenta M, Wagner S, Königsrainer A et al. Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab. 2011; 96: E1126–E1130. doi: 10.1210/jc.2010-2017 PMID: 21490074

35. Silbernagel G, Kovarova M, Cegan A, Machann J, Schick F, Lehmann R et al. High hepatic SCD1 activity is associated with low liver fat content in healthy subjects under a lipogenic diet. J Clin Endocrinol Metab. 2012; 97: E2288–E2292. doi: 10.1210/jc.2012-2152 PMID: 23015656
36. Stefan N, Kantartzis K, Haring HU. Causes and metabolic consequences of Fatty liver. Endocr Rev. 2008; 29: 939–960. doi: 10.1210/er.2008-0009 PMID: 18723451

37. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011; 332: 1519–1523. doi: 10.1126/science.1204265 PMID: 21700865

38. Lamia KA, Papp SJ, Yu RT, Barish GD, Uhlenhaut NH, Jonker JW et al. Cryptochromes mediate rhythmic repression of the glucocorticoid receptor. Nature. 2011; 480: 552–556. doi: 10.1038/nature10700 PMID: 22170608

39. Zhang EE, Liu Y, Dentin R, Pongsawakul PY, Liu AC, Hirota T et al. Cryptochrome mediates circadian regulation of cAMP signaling and hepatic gluconeogenesis. Nat Med. 2010; 16: 1152–1156. doi: 10.1038/nm.2214 PMID: 20852621

40. Narasimamurthy R, Hatori M, Nayak SK, Liu F, Panda S, Verma IM. Circadian clock protein cryptochrome regulates the expression of proinflammatory cytokines. Proc Natl Acad Sci U S A. 2012; 109:12662–12667. doi: 10.1073/pnas.1209965109 PMID: 22778400